ISSUES OF PATHOGENESIS AND TREATMENT OF UTERINE CERVICAL DISEASES ASSOCIATED WITH PAPILLOMAVIRUS INFECTIONS
Abstract
Uterine cervical cancer is on the 3rd place of cancerous diseases morbidity in Russia. Uterine cervical cancer is caused by persistent papillomavirus infection (PVI), therefore the main factor of uterine cervical cancer prevention is screening and vaccination against human papillomavirus (HPV). Uterine cervical cells infection with HPV is necessary, but not sufficient for their malignancy. Its important to provide adequate therapeutic measures to eliminate HIV from the organism, if infection already occurred. One of the effective methods of PVI complex conservative therapy is stimulation of cell immunity by use of natural purine analogue inosine pranobex (IP) as an immunostimulator. IP antivirus effect is associated with suppression of replication of DNA and RNA viruses by bounding to cell ribosome. Immunomodulating capacity of IP is characterized by stimulation of nonspecific immunity, enhanced interleukin production, increased antibodies synthesis, stimulation of chemotaxic and phagocytous activity of monocytes and macrophagues and polymorphonuclear cells. In present article data on open and double blind placebo-controlled studies of IP are summarized. These studies confirm IP efficacy in HPV-infection therapy.
About the Authors
A. L. Unanyan
I.M. Sechenov First Moscow State Medical University (MSMU), State Educational Institution of Higher Professional Training of the Ministry of Healthcare and Social Development
Russian Federation
Russian Federation
L. S. Sidorova
I.M. Sechenov First Moscow State Medical University (MSMU), State Educational Institution of Higher Professional Training of the Ministry of Healthcare and Social Development
Russian Federation
Russian Federation
Yu. M. Kossovich
I.M. Sechenov First Moscow State Medical University (MSMU), State Educational Institution of Higher Professional Training of the Ministry of Healthcare and Social Development
Russian Federation
Russian Federation
Yu. A. Rzyanina
I.M. Sechenov First Moscow State Medical University (MSMU), State Educational Institution of Higher Professional Training of the Ministry of Healthcare and Social Development
Russian Federation
Russian Federation
A. E. Kadyrova
I.M. Sechenov First Moscow State Medical University (MSMU), State Educational Institution of Higher Professional Training of the Ministry of Healthcare and Social Development
Russian Federation
Russian Federation
References
1. Вакцинальная профилактика рака шейки матки, информационно-методическое письмо//Министерство здравоохранения Московской области, Московский областной НИИ акушерства и гинекологии. Москва -2008
2. Дижевская Е.В., Блинов Д.В. Урогенитальные инфекции: современный взгляд. Акушерство, гинекология и репродукция. 2011; 4: 48-56
3. Долгушина В.Ф., Ахматова А.Н., Беренда М.А. Эффективность изопринозина в лечении хронического цервицита, ассоциированного с папилломавирусной инфекцией. Фарматека. 2009; 14.
4. Забелев А.В., Долматова О.К., Сивоконева Е.Н. и др. Результаты кольпоскопического скрининга и опыт применения Изопринозина в лечении папилломавирусных поражений шейки матки. Фарматека. 2005; 3: 72-5.
5. Караулов А.В., Блинов Д.В. Профилактика и лечение заболеваний, вызываемых вирусом папилломы человека. Вакцинация. 2011; 1: 37-42
6. Кедрова А.Г., Подистов Ю.И., Кузнецов В.В. и др. Роль противовирусной терапии в комплексном лечении больных эпителиальными дисплазиями и преинвазивным раком шейки матки. Гинекология. 2005; 7: 170-174.
7. Киселев В.И. Вирусы папилломы человека в развитии рака шейки матки. Димитрейд График Групп. Москва. 2004.
8. Линаск Л.И., Григорьева Е.Е. Опыт применения Изопринозина при заболеваниях шейки матки на фоне папилломавирусной инфекции у подростков и молодых женщин. Рус. мед. журн. 2008; 16 (19).
9. Молочков В.А., Киселев В.И., Рудых И.В., Щербо С.Н. Папилломавирусная инфекция -клиника, диагностика, лечение. Пособие для врачей. Русский врач. Москва. 2004.
10. Прилепская В.Н., Роговская С.И., Кондриков Н.И., Сухих Г.Т. Папилломавирусная инфекция: диагностика, лечение, профилактика. Пособие для врачей. Москва. 2007.
11. Чиссов В.И., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2008 г. Госкомстат России. Москва. 2009; 192 с.
12. Antinore M.J., Birrer M.J., Patel D. et al. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP-1 family of transcription factors. EMBO J. 1996; 15: 1950-1960
13. Fiedler M., Muller-Holzner E., Viertler H.P. et al. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J. 200; 18(10): 1120-1122
14. Liu X., Han S., Baluda M.A., Park N.-H. HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes. Oncogene. 1997; 14: 2347-2353
15. Mohanty K.C., Scott C.S. Immunotherapy of genital warts with inosine pranobex (Imunovir): preliminary study. Genitourin Med. 1986; 62: 352-355
16. Munger K., Phelps W.C., Bubb P.M. et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989; 63: 4417-4421
17. Munoz N., Kato I., Bosch F.X. et al. Risk factor for HPV DNA detection in middle-aged women. Sex Transm Dis. 1996; 504-510
18. Ostor A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993; 12(2): 186-192
19. Sherman M.E., Schiffman M.H., Lorincz A.T. et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J of Clin Path. 1994; 102: 182-187
20. Shin K.-H., Ahn J.H., Kang M.K. et al. HPV-16 E6 oncoprotein impairs the fidelity of DNA end-joining via p53-dependent and -independent pathways. Intern J Oncol. 2006; 28: 209-215
21. Tay S.K. Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized doubleblinded placebo controlled study. Int J STD AIDS. 1996; 7(4): 276-280.
22. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248: 76-79
23. Yim E.-K., Park J.-S. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005; 37(6): 319-324
For citation:
Unanyan A.L., Sidorova L.S., Kossovich Yu.M., Rzyanina Yu.A., Kadyrova A.E. ISSUES OF PATHOGENESIS AND TREATMENT OF UTERINE CERVICAL DISEASES ASSOCIATED WITH PAPILLOMAVIRUS INFECTIONS. Obstetrics, Gynecology and Reproduction. 2012;6(1):27-30. (In Russ.)
Views: 245
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
